Login to Your Account

Gilead Beats Consensus; HIV Drugs Driving Growth

By Jennifer Boggs

Thursday, October 20, 2005
Riding the growth of its HIV franchise, Gilead Sciences Inc. reported solid earnings for the third quarter, beating consensus estimates by a penny. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription